News: Articles and Publications

MAM01 and L9LS Demonstrate Equipotent Protection Against Plasmodium falciparum (Pf) Malaria Infection in Mice

February 14, 2024•Publication

Overview of PAN-TB Ph 2b/c Treatment Shortening Trial

February 14, 2024•Publication

The Development of A Long- Acting Intervention to Prevent P. falciparum Malaria

February 14, 2024•Publication

Patient Centric Sampling in the Therapeutic Development Programs

February 14, 2024•Publication

Safety and immunogenicity of the investigational tuberculosis vaccine M72/AS01E-4 in people living with HIV

November 16, 2023•Publication

A randomized, active-control, open-label phase 2a trial evaluating the bactericidal activity, safety, and pharmacokinetics of TBA-7371 in drug-susceptible pulmonary tuberculosis

November 16, 2023•Publication

Immune Correlates of Protection for BCG and M72 TB Vaccines

November 16, 2023•Publication

Patient Centricity: One BloodDraw at a Time

October 23, 2023•Publication

Implementing a patient-centric sampling strategy in the global clinical development of RSM01 (Anti-RSV mAb)

July 2, 2023•Publication

Calibr and Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Candidate Tuberculosis Treatment Compound

February 15, 2023•Press Release, Written by Gates MRI

Calibr, a division of Scripps Research dedicated to the “bench to bedside” development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment.

Immunogenicity Risk Assessment and Integrated Summary of Immunogenicity

December 6, 2022•Publication

Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Candidate Tuberculosis Antibiotics

October 18, 2022•Press Release, Written by Gates MRI

Merck and the Bill & Melinda Gates Medical Research Institute today announced a licensing agreement for two preclinical antibacterial candidates for evaluation as potential components of combination regimens for the treatment of tuberculosis (TB).

Developing Tuberculosis Vaccines for People with HIV: Consensus Statements from an International Expert Panel

October 11, 2022•The Lancet

Gate MRI’s Head of Vaccine Development, Alex Schmidt, joins a panel of international experts on a recent consensus statement for the development of TB vaccines in those with HIV. The paper outlines recommendations for vaccine developers on which vaccines, patient populations, and efficacy endpoints to prioritize when investigating a TB vaccine in individuals with HIV as well as ethical and regulatory factors to consider.

TB Immune Correlates of Protection

September 1, 2022•Publication

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials

August 17, 2022•Press Release

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) — among Janssen Pharmaceutica NV, Otsuka, TB Alliance and the Bill & Melinda Gates Medical Research Institute — supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development.